Patents

US 12747228 B2: Potent and selective inhibitors of IRAK4

Granted
2026-09-29
Filed
2022-09-08 application 18690160
Type
Utility · 18 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

The disclosure relates to compounds that act as inhibitors of interleukin 1 (IL-1) receptor-associated kinase 4 (IRAK4); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.

Source: PTBLXML, file of 2026-09-29 (ipgb20260929.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
DANA-FARBER CANCER INSTITUTE, INC. 892 patentsUS company or organizationBoston, MADANA-FARBER CANCER INSTITUTE, INC. Federal lobbying client EXACT high confidence: identical full name and state
DANA-FARBER CANCER INSTITUTE Nonprofit FUZZY medium confidence: same name (governing-board words and legal endings aside) and state
PTBLXML, file of 2026-09-29

Inventors

InventorPlacePatentsPerson pageSource
John M. HatcherBoston, MAPTBLXML, file of 2026-09-29
Nathanael S. GrayJamaica Plain, MA178PTBLXML, file of 2026-09-29

CPC categories

SubclassCategoryFirst groupSource
C07DHeterocyclic compoundsC07D401/14PTBLXML, file of 2026-09-29
A61KPreparations for medical, dental or toiletry purposesA61K31/4545PTBLXML, file of 2026-09-29

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

No recorded assignments or security interests on file for this patent.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.